LSI USA '25 Almost at Capacity: Register Today arrow-icon
Jan 31, 2025

The Weekly Recap 1/31/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

The Weekly Recap 1/31/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

Weekly Recap 16_9 - 1.31.2025

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $81M in new funds, complete a first-in-human trial, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).

BrightHeart

Appointed Amanda French as Chief Strategy Officer to lead product, marketing, and business development efforts. With a background in medical devices, women’s health, and digital health—including her experience as the founding CEO of Emme—French will help drive BrightHeart’s next phase of growth.

EBAMed

Received an investment from CDP Venture Capital as part of the PNRR (Piano Nazionale di Ripresa e Resilienza) and the Next Generation EU initiative. EBAMed is developing CardioKit, an ultrasound imaging solution to provide non-invasive treatment of cardiac arrhythmias.

Field Medical

Raised $26.87M in new funds following FDA TAP Pilot acceptance and Breakthrough Device Designation in December 2024 for its FieldForce Ablation System. FieldForce is the first and only pulsed-field ablation (PFA) system designed specifically for ventricular arrhythmia ablation.

Imaginostics

Appointed Valerie Gharagouzloo as Chief Executive Officer as the company prepares for its next phase of growth. The company is developing non-invasive diagnostic vascular imaging technology using its breakthrough quantitative imaging biomarkers.

iotaMotion

Completed its Series B funding round and announced that 25 centers in the United States now offer the iotaSOFT Insertion System. iotaSOFT is the first and only robotic-assisted platform available in the United States for cochlear implant electrode array insertion.

Lumicell

Announced the U.S. launch and first commercial use of its LumiSystem. LumiSystem, the first and only fluorescence-guided imaging system for breast cancer detection, provides real-time illumination of cancerous tissue in the breast cavity during initial lumpectomy.

Neuronoff

Received $5M in funding from the DOD and NIH to advance its Injectrode neuromodulation technology. DOD funding will support a randomized controlled trial for treating neurogenic bladder following spinal cord injury, and NIH funding will support preclinical research in treating overactive bladder.

Novadip Biosciences

Shared promising 12-month results from its Phase 1b/2a Trial of NVD003 for Treating Congenital Pseudarthrosis of the Tibia (CPT). NVD003 is an autologous therapy derived from adipose stem cells (ASC), offering a potential single treatment option for preserving limbs and improving mobility in children with CPT.

Quibim

Announced the close of a $50M Series A funding round led by Asabys and Buenavista. The funds will support the growth of Quibim’s product pipeline and AI models and help the company drive commercial growth.

Rhaeos

Announced that the company has moved into its new lab space in Chicago’s Fulton Market neighborhood to grow its FlowSense platform technology and wearable patch. The patch is a non-invasive, wireless skin patch designed to monitor fluid flow subdermally throughout the body.

Spiro Robotics

Successfully completed a first-in-human trial of Spiro-VISTA, an image-guided tracheal intubation device. In the trial—which involved 30 patients with highly complex and challenging airways—all patients were successfully intubated on the first attempt.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.